| 000 | 01823 a2200493 4500 | ||
|---|---|---|---|
| 005 | 20250517032452.0 | ||
| 264 | 0 | _c20151201 | |
| 008 | 201512s 0 0 eng d | ||
| 022 | _a1473-4877 | ||
| 024 | 7 |
_a10.1185/03007995.2015.1021906 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aXie, Jipan | |
| 245 | 0 | 0 |
_aComparative effectiveness of everolimus-based therapy versus endocrine monotherapy among postmenopausal women with HR+/HER2- metastatic breast cancer: a retrospective chart review in community oncology practices in the US. _h[electronic resource] |
| 260 |
_bCurrent medical research and opinion _cJun 2015 |
||
| 300 |
_a1095-103 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article; Research Support, Non-U.S. Gov't | ||
| 650 | 0 | 4 | _aAdult |
| 650 | 0 | 4 | _aAged |
| 650 | 0 | 4 | _aAged, 80 and over |
| 650 | 0 | 4 |
_aAntineoplastic Combined Chemotherapy Protocols _xtherapeutic use |
| 650 | 0 | 4 |
_aBreast Neoplasms _xdrug therapy |
| 650 | 0 | 4 | _aDisease-Free Survival |
| 650 | 0 | 4 |
_aEverolimus _xadministration & dosage |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 | _aKaplan-Meier Estimate |
| 650 | 0 | 4 | _aMiddle Aged |
| 650 | 0 | 4 |
_aNeoplasm Recurrence, Local _xdrug therapy |
| 650 | 0 | 4 | _aPostmenopause |
| 650 | 0 | 4 | _aProportional Hazards Models |
| 650 | 0 | 4 |
_aReceptor, ErbB-2 _xmetabolism |
| 650 | 0 | 4 | _aRetrospective Studies |
| 650 | 0 | 4 | _aTreatment Outcome |
| 700 | 1 | _aHao, Yanni | |
| 700 | 1 | _aLi, Nanxin | |
| 700 | 1 | _aLin, Peggy L | |
| 700 | 1 | _aOhashi, Erika | |
| 700 | 1 | _aKoo, Valerie | |
| 700 | 1 | _aSignorovitch, James E | |
| 700 | 1 | _aWu, Eric Q | |
| 700 | 1 | _aYardley, Denise A | |
| 773 | 0 |
_tCurrent medical research and opinion _gvol. 31 _gno. 6 _gp. 1095-103 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1185/03007995.2015.1021906 _zAvailable from publisher's website |
| 999 |
_c24898295 _d24898295 |
||